©The Author(s) 2025.
World J Gastrointest Oncol. Dec 15, 2025; 17(12): 112548
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112548
Published online Dec 15, 2025. doi: 10.4251/wjgo.v17.i12.112548
Table 1 Baseline characteristics of 13 patients included in this study, n (%)
| Characteristics | |
| Gender | |
| Male | 9 (69.2) |
| Female | 4 (30.8) |
| Age, years | |
| < 65 | 6 (46.2) |
| ≥ 65 | 7 (53.8) |
| Underlying chronic diseases | |
| Positive | 8 (61.5) |
| Negative | 5 (38.5) |
| RAS mutation | |
| Positive | 5 (38.5) |
| Negative | 3 (23.1) |
| Unknown | 5 (38.5) |
| Radical surgery | |
| Positive | 3 (23.1) |
| Negative | 10 (76.9) |
| Number of metastatic sites | |
| 1 | 4 (30.8) |
| ≥ 2 | 9 (69.2) |
| ECOG performance status score | |
| 0 | 9 (69.2) |
| 1 | 4 (30.8) |
- Citation: Meng XY, Cai YM, Sun NN, Zhang WH, Cui RX, Zhang L, Zheng CC, Sun Z, Luo WX, Wang FW. Preliminary exploration of programmed death 1 inhibitor combined with fruquintinib and docetaxel for advanced colorectal cancer. World J Gastrointest Oncol 2025; 17(12): 112548
- URL: https://www.wjgnet.com/1948-5204/full/v17/i12/112548.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i12.112548